They found that the PDAS was not only valid but also feasible and practical for use in daily practice [36]. Moreover, the authors point out that One important benefit of replacing the DAS28 with the PDAS

is that the PDAS will involve patients far more directly in assessing their disease, Hydroxychloroquine mouse which is widely considered to be important in optimizing care. [36] For these reasons, Long and Dixon have proposed that we use additional standards when we assess outcome measures for use in the clinic, rather than for research. They state Traditional measurement criteria, stressing reliability, validity and responsiveness to change, must be supplemented by criteria of feasibility of use, clinical utility and acceptability. [37] Across Canada, the HJHS has been

incorporated into the CHIR-99021 in vitro annual assessment for boys with haemophilia. This has been useful – both for the detection of early change in the joints, as well as for research purposes. In other clinics, routine evaluation of outcome measures has also been used. For example, in Vellore, India, the team has used the Canadian Occupational Performance Measure for developing therapy goals and treatment plans [38]. We now have a number of haemophilia-specific outcome measures with excellent measurement properties. In other fields, it has been shown that routine use of standardized outcome measures can improve the quality of care. It would seem that there is a strong research imperative to study the use of practical, validated haemophilia measures as a way of improving our daily practice. Dr. Feldman holds peer-review grants from Bayer and Baxter. He sits on DSMBs for Novartis and Pfizer. “
“Division of Critical Care Medicine, Department of Anesthesia, Perioperative and Pain Medicine at Boston Children’s Hospital Division of Blood Diseases and Resources at the National Heart, Lung and Blood Institute Clinical hip abnormalities, secondary to recurrent joint and/or muscle bleeding in persons with haemophilia, have not been well characterized and have the potential for significant morbidity. We aimed to examine the prevalence of clinical hip abnormalities in the

US haemophilia population and to explore associations between these findings and putative risk factors. We conducted this website a study of hip abnormalities of 8192 subjects aged 2–69 years with haemophilia A and haemophilia B (54% of haemophilia A and haemophilia B are severe) currently enrolled in the Universal Data Collection (UDC) database. Associations between hip abnormality and type/severity of haemophilia A/B, current age, history of high-titre (≥5 BU) inhibitor (HTinh), concomitant ankle (AA) and knee arthropathy (KA), overweight and obesity and prophylaxis were examined using logistic regression. Overall prevalence of hip abnormality at the last recorded UDC visit for all subjects was 16.7%. Haemophilia A (aOR = 1.3, 1.0–1.